Overview of the patent and exclusivity landscape for major peptide drugs, including upcoming expirations and biosimilar/follow-on product opportunities.
Filed under industry market, written for investor, founder-operator, researcher.
Not medically reviewed. Last updated 2026-04-20. Nothing here is medical advice.
The patent landscape for peptide therapeutics is creating significant opportunities for biosimilar and follow-on peptide products. Understanding this landscape is essential for industry professionals and investors.
Protect the peptide sequence and specific modifications (acylation, PEGylation, amino acid substitutions). These are the strongest form of patent protection.
Protect specific drug delivery systems, excipient combinations, or device designs. Often extend protection beyond composition patents.
Protect specific therapeutic indications. A peptide might have expired composition patents but active method-of-use patents for specific conditions.
Protect specific synthesis or purification methods. Generally easier to design around than composition patents.
Several blockbuster peptide drugs face patent cliffs in the coming years. Key categories include:
For peptides approved as biologics, the biosimilar pathway (351(k)) requires demonstrating biosimilarity to the reference product. For peptides approved as drugs, generic pathways may apply.
The peptide patent landscape creates opportunities in:
This article provides industry analysis and does not constitute investment advice.
More guides: All guides, Safety centre, Peptide library.